Non-stimulatory self peptide MHC (pMHC) complexes do not induce T cell activation and effector functions, but can enhance T cell responses to agonist pMHC, through a process termed co-agonism. This protocol describes an experimental system to investigate co-agonism during human CD8+ T cell activation by expressing human MHC class I molecules presenting pre-determined peptides as single polypeptides (single chain MHC) in a xenogeneic cell line. We expressed single chain MHCs under conditions where low levels of agonist single chain p-MHC complexes and high levels of non-stimulatory single chain p-MHC complexes were expressed. Use of this experimental system allowed us to compare CD8+ T cell responses to agonist pMHC in the presence or absence of non-stimulatory pMHC. The protocol describes cell line transfection with single chain MHC constructs, generation of stable cell lines, culture of hepatitis B virus-specific human CD8+ T cells and T cell activation experiments simultaneously quantifying cytokine production and degranulation. The presented methods can be used for research on different aspects of CD8+ T cell activation in human T cell systems with known peptide MHC specificity.
Introduction
MHC class I (MHC-I) molecules present short (8-10 amino acids) peptides derived from proteins synthesized by each cell. MHC-I molecules on healthy cells present self peptides derived from endogenous proteins. Viral infection leads to presentation of non-self virus-derived peptides on MHC-I, but even infected cells present non-self peptides in the presence of large amounts of self peptide-MHC (pMHC). MHC-I is recognized by the T cell receptor (TCR) and the CD8 co-receptor on T cells. TCR binding affinity to peptide pMHC is highly dependent on the sequence of presented peptides, whereas CD8 binding is peptide-independent. TCR binding to non-self agonist pMHC complex leads to T cell activation and effector functions. Non-stimulatory self pMHC complexes do not induce T cell activation and effector functions, but can enhance T cell responses to agonist pMHC, through a process termed co-agonism 1, 2, 3 . Co-agonism has been observed in mouse CD4+ T cells 4, 5, 6 as well as in mouse and human CD8+ T cells 7, 8, 9, 10, 11, 12, 13 . Under physiological conditions, T cells need to recognize limited quantities of agonist pMHC on antigen presenting cells (APCs) co-presenting high levels of non-stimulatory pMHC complexes, suggesting that co-agonism contributes to optimal T cell responses in vivo. Total cell surface MHC class I levels are frequently downregulated during viral infections 14 and on tumors 15 . This immune evasion strategy decreases agonist pMHC presentation, but also reduces the amount of co-agonist pMHC I available for T cell activation enhancement. Moreover, high cell surface expression levels of the MHC class I molecule HLA-C have been shown to correlate with improved HIV control 16 , suggesting a critical role for total MHC class I expression in T cell activation. Despite the physiological significance of co-agonism, its molecular mechanism is still incompletely understood. This is largely due to technical challenges of experimentally controlling the amount of presented co-agonist pMHC while keeping agonist pMHC constant.
We developed an experimental system to investigate co-agonism during human CD8+ T cell activation by expressing human MHC class I molecules presenting pre-determined peptide as single polypeptide (single chain MHC-I, Figure 1A ) in a xenogeneic cell line . Early work on co-agonism in CD8+ T cell activation in the context of agonist pMHC recognition on APC used TAP2-deficient cell lines as APCs. TAP is required for peptide transport from the cytoplasm to the endoplasmic reticulum, and TAP-deficiency severely reduces the pool of available MHC class I-binding peptides. In the absence of peptides, the nascent complex of MHC class I heavy chain and β 2 -microglobulin is unstable, resulting in very low MHC-I cell surface expression. Initially, comparison of T cells stimulated with antigen loaded on TAP-sufficient and -deficient mouse RMA and RMA-S cell lines, respectively, as APCs, did not reveal any evidence for co-agonism during mouse T cell activation 18 . However, use of this experimental system did not allow precise control over the amount of agonist pMHC presented independently of non-stimulatory self pMHC. Moreover, these two cell lines may also differ in expression of other molecules that modulate T cell activation, such as ligands to T cell co-stimulatory or inhibitory receptors, or adhesion molecules.
Subsequently, we developed a protocol for loading TAP2-deficient RMA-S cells with exogenous peptides to allow presentation of a fixed amount of agonist pMHC in the presence or absence of non-stimulatory pMHC. This was achieved through the following: incubation of TAP2-deficient RMA-S cells at lower temperatures (28 °C, instead of the usual 37 °C) to stabilize empty MHC class I heavy chain/β 2 microglobulin complexes 19 ; incubation at 28 °C with exogenous agonist peptide; incubation at 28 °C in the presence or absence of exogenous non-stimulatory peptide; and incubation at 37 °C to reduce cell surface expression of empty MHC class I complexes 8, 9 . Use of this experimental set-up revealed that the presence of non-stimulatory pMHC enhanced activation of mouse thymocytes, naïve peripheral CD8+ T cells and CTLs 8 . Mechanistically, the presence of non-stimulatory pMHC can induce CD8 recruitment to the T cell:APC immune synapse even in the absence of agonist pMHC, and non-stimulatory pMHC can enhance TCR interaction with CD8 coreceptor 7, 8 . However, this experimental system does not allow testing the relative contributions of TCR and CD8 coreceptor binding to agonist and co-agonist pMHC in mediating the activation enhancement, as any modifications altering TCR or CD8 binding to MHC class I would affect all MHC molecules, regardless of the presented peptide. We therefore used MHC class I single chain technology to overcome this problem.
The single chain (sc) MHC class I format has been used before to improve antigenic pMHC presentation for therapeutic strategies, and to answer fundamental questions on mechanisms of TCR and NK cell receptor activation and function 20, 21 . scMHC-I consists of peptide, β 2microglobulin and MHC-I heavy chain joined by two flexible serine/glycine-rich linkers (Figure 1A) , several different linker sequences have been developed and tested 22 . scMHC-I can fold independently of the TAP complex and chaperone proteins required for conventional pMHC complex assembly 20 . scMHC-I have been shown to fold correctly, as determined using conformation-specific antibody staining 22 and by solving sc structure with X-ray crystallography 23 . The basic scMHC-I design has been modified to improve binding of low affinity peptides 24, 25 . This protocol describes the use of human scMHC-I to investigate co-agonism during human CTL clone activation. The protocol has been optimized for human CTL clone specific for an epitope of Hepatitis B virus (HBV). HBV is a severe healthcare burden worldwide, as there are 350 million people infected with HBV and chronic HBV infection can lead to development of hepatocellular carcinoma (HCC). HCC cells resulting from HBV infection can usually present HBV-derived epitopes and can be recognized by specific human T cells. HBV and HCC clearance relies on the human T cell responses 26 , but HCC patients often suffer from T cell exhaustion and reduced T cell responses 27 . Introduction of HBV-specific TCR into T cells of HBV has been tried as a potential immunotherapy strategy to eliminate chronic HBV infection 28 . However, it is unknown if this method will be effective in a clinical setting, due to the low levels of surface MHC-I in human hepatocytes 29 . Therefore, understanding the mechanism of coagonism may provide alternative perspectives for immunotherapy of HBV, possibly by enhancing the presentation of endogenous pMHC to induce co-agonism-mediated T cell responses. The protocol covers all the necessary steps for research on human co-agonism: transfection of T-REx CHO cells with agonist and co-agonist sc pMHC, generation of stable T-REx CHO cell lines, culture of HBV-specific human CTL CD8+ T cell line and CTL activation experiments quantifying cytokine production and degranulation in response to T-REx CHO cells. Although we focus on using the sc MHC class I technology to investigate co-agonism during HBV T cell activation, it must be noted that the presented methods can easily be adapted for research on other aspects of T cell activation in human T cell systems with known pMHC-I specificity.
This protocol uses a human CD8+ CTL line specific for HBV-derived peptide E183-91 (FLLTRILTI: "E183") 30 presented on HLA-A2. sc HLA molecules consisting of a signal sequence from human β2-microglobulin, a HLA-A2 binding peptide of interest, a glycine/serine linker, a human β2-microglobulin, a glycine/serine linker and a A2 heavy chain can be commercially synthesized ( Figure 1A) . Plasmids encoding scA2 constructs with agonist E183 peptide, or coagonist HIV GAG (SLYNTVATL) 31 peptides are available from the authors upon request. The peptide sequence can be changed using site directed-mutagenesis. A tetracycline-inducible vector pcDNA5/TO was used to express the agonist single chain HLA-A2 with E183 peptide (sc E183-HLA-A2). In the presence of tetracycline repressor, the pcDNA5/TO plasmid allows only very low, "leaky" expression of the protein of interest; high expression can be induced by the addition of tetracycline (Figure 1B,C) . Use of a tetracyclineinducible expression system allows control over the amount of cell surface agonist pMHC expression. A constitutive expression plasmid pcDNA3.1 was used to express coagonist scA2 with GAG peptide (sc GAG-HLA-A2). The tetracycline-regulated expression (T-REx) CHO cell line (hamster cell line, no endogenous human MHC) was used to express agonist and co-agonist sc-HLA-A2 constructs. This experimental system allows precise control over pMHC presentation ( Figure 1C) : no pMHC presentation (untransfected T-REx), a high amount of co-agonist pMHC presentation (constitutive sc GAG-HLA-A2 expression), a low amount of agonist pMHC presentation (sc E183-HLA-A2 in the absence of tetracycline), a high amount of agonist pMHC presentation (sc E183-HLA-A2 in the presence of tetracycline), a low amount of agonist pMHC presentation and high expression of co-agonist pMHC (sc E183-HLA-A2 in the absence of tetracycline, and constitutive sc GAG-HLA-A2 expression). Use of this experimental system allows precise control of cell surface amounts of agonist and coagonist pMHC.
CHO Cell Transfection and Generation of Stable CHO Cell Lines

CHO cell transfection NOTE:
This section describes CHO cell transfection using polyethylenimine (PEI). However, alternative methods can be used, as CHO cells are relatively easy to transfect using commercially available lipid transfection reagents. 1. Culture CHO cells in complete F12 (cF12, F12 supplemented with 5% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin and 10 µg/mL blasticidin to maintain expression of the tetracycline repressor). Passage the cells every 3-4 days at a 1:10 ratio. 2. One day before transfection, prepare the CHO cell suspension. Wash CHO cells in the flask using PBS (10 mL for PBS for a T75 flask, 5 mL PBS for a T25 flask). Add 0.05% Trypsin/0.02% EDTA in PBS (2 mL for a T75 flask, 1 mL for a T25 flask) to the flask and incubate for 5-10 min at room temperature (RT). Using a light microscope, check that the cells have detached, and stop trypsinization by adding cF12 to the flask (8 mL for a T75 flask, 4 mL for a T25 flask). 3. Transfer the CHO cell suspension to a 15 mL tube, and centrifuge at 300-400 x g for 5 min at 4 °C or RT. Remove supernatant, resuspend in cF12 (10 mL for a T75 flask, 5 mL for a T25 flask) and count using a hemocytometer. 4. Adjust cell concentration to 60,000-100,000 CHO cells/mL. Add 5 mL of CHO cell suspension (300,000-500,000 CHO cells) per well in a 6 well plate. Incubate overnight at 37 °C, 5% CO 2 . 5. On the day of the transfection, add 400 μL of serum-free F12 media or low serum media to a 1.5 mL tube. Add 3 μg of plasmid to 400 μL of media. Mix by pipetting. Add 6 μg of PEI (6 μL of 1 mg/mL PEI solution) to the media/DNA mix, and vortex immediately for 10 s. 6. Incubate the media/DNA/PEI mix at RT for 10-15 min. During this incubation, replace CHO cell media in the 6 well plate with 5 mL of fresh cF12 media. 7. Add the media/DNA/PEI solution to CHO cells. Add the solution dropwise and evenly over the well. Incubate overnight at 37 °C, 5% CO 2 .
2. Generation of stable CHO cell lines 1. One day after transfection, remove media from the wells and add 5 mL of cF12 containing the appropriate selection antibiotics to each well. Use 0.3 mg/mL hygromycin for pcDNA5TO-based plasmids, and 1 mg/mL geneticin for pcDNA3-based plasmids. 2. If the cells reach more than 90% confluency at 24 h post transfection, trypsinize the cells. 3. Wash wells with 1 mL of PBS per well, add 1 mL of 0.05% trypsin/0.02% EDTA in PBS and incubate for 5-10 min at RT. Using a light microscope, check that the cells have detached, and stop trypsinization by adding 3-4 mL of cF12 per well. 4. Transfer the CHO cell suspension to a 15 mL tube, and centrifuge at 300-400 x g for 5 min at 4 °C or RT. Remove the supernatant and re-suspend in 10 mL of cF12. Add 5 mL of cell suspension per well in 6 well plate. Use two wells to maximize yield of the transfected cells. 5. Incubate the 6 well plates at 37 °C, 5% CO 2 . Monitor cell death and the growth of resistant colonies using a light microscope. Remove media and replace it with fresh media containing the appropriate antibiotics after 4-5 days, or when significant cell death is observed. 6. Once the resistant cells reach more than 70% confluence, trypsinize the cells as described in step 1.2.2 and transfer to a T25 flask for expansion. The antibiotic selection takes 1-2 weeks. 7. Once the antibiotic-resistant CHO cells in the T25 flask reach 70-80% confluence, perform antibody staining to verify cell surface expression of the constructs of interest. One day before antibody staining, trypsinize the cells as described in step 1.2.2 and adjust the cell concentration to 200,000 cells/mL, and add 1 mL of cell suspension to 12 well plate. For testing of tetracycline-inducible constructs, add 50-60 ng/mL of tetracycline. Incubate overnight at 37 °C, 5% CO 2 . 8. Use cell scraper to detach CHO cells from bottom of the well. This method is preferable to trypsinization, as it reduces the risk of epitope damage due to proteolytic cleavage. 9. Transfer the 1 mL of media containing the CHO cells to a FACS tube. Spin down at 300-400 x g, 4 °C for 5 min. Re-suspend in 100 μL of anti-HLA antibody diluted in FWB. Incubate 30 min at 4 °C on ice. Perform this staining with anti-A2 antibody to detect total A2 cell surface expression levels, and TCR-like antibody specific for A2 in complex with E183 peptide to detect agonist pMHC-I cell surface expression levels. 10. After verifying MHC expression, FACS-sort the positive cells, and maintain the sorted cells in media with antibiotics to reduce transgene loss. For CHO cells expressing agonist pMHC, single cell sorting is recommended, to ensure comparable agonist pMHC expression with and without supertransfection with co-agonist pMHC. 2-3 weeks are required for CHO cell growth following the single cell sorting.
HBV-specific CTL Culture
1. Preparation of PBMCs as feeders for HBV-specific human CTL re-stimulation NOTE: For the A2-E183-specific CTL clone, re-stimulation with freshly isolated PBMCs, rather than thawed PBMCs, gives the best results. CAUTION: Obtain all the necessary ethical approvals before recruiting volunteers for blood donations. For the purpose of this work, PBMC were collected from healthy volunteers under the protocol approved by NUS IRB. Informed consent was obtained from all donors. Follow all the necessary precautions when working with human blood to reduce risk of transmission of blood borne diseases. 1. Before starting, set the centrifuge temperature at 19-20 °C and pre-warm the density gradient (e.g., Ficoll) to RT. 2. Add 15 mL of room temperature density gradient to 50 mL tube. Centrifuge at 400 x g for 5 min at 19-20 °C. This is to ensure there is no density gradient on the side of the tube. Remove approximately 70% of the plasma layer. Carefully aspirate the layer containing the PBMC (the cloudy layer on top of the clear density gradient layer) using a Pasteur pipette and place it in a new 50 mL tube. 6. Add PBS to PBMCs to obtain a 50 mL total volume. Centrifuge tube at 4 °C, 300-400 x g for 10 min. Carefully remove the supernatant using the vacuum aspirator and sterile glass Pasteur pipette, or by decanting. 7. Re-suspend the cells in 50 mL of PBS. Centrifuge tube at 4 °C, 300 x g for 10 min. Carefully remove the supernatant using the vacuum aspirator and sterile glass Pasteur pipette, or by decanting. 8. Re-suspend cells in 2 mL of complete human T cell media (serum free media supplemented with 2% human serum). Count the cells using hemocytometer. This protocol gives on average 1-2 x 10 6 PBMCs per 1 mL of blood used. 1. Plating CHO cells as antigen presenting cells 1. Culture CHO cells in T75 flask, as described in step 1.1.1. Use cells at 70-90% confluence for best results. One day before the T cell activation experiment, trypsinize the cells as described in section 1.1.2. After trypsinization, transfer the cell suspension into a 15 mL tube, centrifuge at 400 x g for 5 min at 4 °C or RT, remove supernatant by pipetting or decanting. 2. Re-suspend the cell pellet in 5 mL of cF12. Count CHO cells using a hemocytometer. 3. Adjust the cell concentration to 2 x 10 5 /mL using cF12. Add 50-60 ng/mL of tetracycline to the agonist only samples to induce high amounts of agonist pMHC-I expression as positive control (Figure 1C) . CHO cells will settle down in 15 mL tubes, so make sure to mix them by pipetting or vortexing before plating. 4. For T cell activation assay, add 100 μL of the CHO cell suspension per well to U-bottom 96 well plate, and use triplicates per CHO cell line. For CHO cell anti-MHC staining, add 1 mL of cell suspension to 12 well plate, and use triplicates per cell line. Incubate overnight at 37 °C, 5% CO 2 .
T Cell Activation Experiments
T cell activation assay NOTE:
This T cell activation assay allows simultaneous quantification of T cell degranulation (CD107a staining, a measure of T cell cytotoxicity) and cytokine production. 1. The day before the experiment, centrifuge CTLs cells at 400 x g at 4 °C for 5 min, count using hemocytometer and re-suspend the cells at 10 6 cells/mL in complete human T cell media without cytokines or PHA. Incubate at 37 °C, 5% CO 2 . The purpose of this rest step is to reduce CTL sensitivity, as we have observed maximum activation in response to low amounts of antigen without this step. 2. On the day of the experiment, centrifuge T cells at 400 x g at 4 °C for 5 min, remove the supernatant by decanting or pipetting, and resuspend the cells in 2 mL complete serum-free media (without cytokines or PHA). Count live T cells using a hemocytometer, and adjust T cell concentration to 10 6 live cells/mL using complete human T cell media (without cytokines or PHA). 1. Perform this staining with anti-A2 antibody to detect total A2 cell surface expression levels, and TCR-like antibody specific for A2 in complex with E183 peptide 32 to detect agonist pMHC-I cell surface expression levels.
Add anti-human
3. Add 1 mL of FWB to each CHO sample, spin down at 300-400 x g, 4 °C, 5 min, and then re-suspend the sample in 0.3 mL of FWB. Proceed with flow cytometry analysis.
Representative Results
The sc MHC class I technology used here allows precise control of cell surface expression of MHC class I with known, covalently linked peptides, to induce T cell activation. We have generated an engineered xenogeneic APC system (Figure 1A,B,C) that allows presentation of low levels of agonist pMHC in the presence or absence of co-agonist pMHC (Figure 1D,E) . Critically, we have used a TCR-like antibody specific for HLA-A2 presenting E183 peptide to show that presentation of the agonist sc E183-HLA-A2 is not altered by co-expression of co-agonist sc GAG-HLA-A2 (Figure 1E) . However, it must be noted that the E183-HLA-A2 specific TCR-like antibody shows some binding to HLA-A2 presenting GAG peptide (Figure 1E) . Similar engineered antigen presenting cell systems can be constructed using different peptides or MHC molecules to investigate molecular requirements for TCR and/or coreceptor interactions in human T cells with different specificities.
We used these engineered APCs to stimulate an E183-HLA-A2-specific human CD8+ T cell clone. Three negative controls were used: T cells only, untransfected T-REx CHO cells, and T-REx CHO cells expressing high amounts of co-agonist sc GAG-HLA-A2 to test for potential T cell activation by any molecules expressed on T-REx CHO cells (untransfected T-REx CHO cells as compared to T cell only), and for T cell activation by sc-GAG-HLA-A2 (T-REx CHO cells expressing high levels of sc-GAG-HLA-A2 as compared to untransfected T-REx CHO cells).
Untransfected T-REx CHO cells or T-REx CHO cells expressing sc-GAG-HLA-A2 did not induce activation of E183-HLA-A2-specific CD8+ CTL clone, as determined by quantifying IFN-γ production and expression of degranulation marker CD107a as a measure of T cell cytotoxicity (Figure 2A,B) . Expression of high levels of agonist sc E183-HLA-A2, used as positive control, induced very efficient IFN-γ production and degranulation (Figure 2A,B) , demonstrating that the sc HLA-A2 construct can be recognized by a specific TCR to activate T cell effector functions. Expression of low levels of sc E183-HLA-A2 induced lower levels of IFN-γ production and degranulation, and this was enhanced by presence of co-agonist sc GAG-HLA-A2 (Figure 2A,B) . It must be noted that very high percentages of CD107a+ T cells were observed even in response to low levels of antigenic pMHC (Figure 2B) , consistent with previous reports of relatively low requirements for the amount of agonist pMHC for induction of T cell cytotoxicity 33 . The CD107a MFI, indicating the amount of degranulation on a single cell basis, provides a better dynamic range (Figure 2B) . The T cell activation assay used allows simultaneous quantification of two major effector functions: cytokine production and cytotoxicity, and provides very sensitive readout with good dynamic range.
We used the single chain technology to test whether TCR binding to co-agonist pMHC is required for co-agonist pMHC-dependent activation enhancement. We mutated valine at position 152 at the edge of the HLA-A2 peptide binding groove (Figure 3B) to glutamic acid to create V152E mutant, as this mutation has been reported to abolish TCR binding to HLA-A2 34 . We then tested if the V152E mutation can abolish TCR binding for the E183-HLA-A2 CTL clone used, by introducing this mutation into agonist sc E183-HLA-A2 and expressing the mutant agonist sc construct in T-REx CHO cells. Wild type, but not V152E, sc E183-HLA-A2 induced activation of the E183-HLA-A2-specific CTL clone used (Figure 3A) . It must be noted that any TCR-binding mutation on MHC class I needs to be separately tested for each individual TCR/T cell clone used, as the effect of mutation will depend on the precise molecular interactions between TCR and pMHC complex, and these will differ between different TCRs. For example, we tested eight mutations, either previously reported TCR-binding mutations or mutations predicted to disrupt TCR binding without abrogating peptide binding into HLA-A2. Of these, V152E was the only mutation that abolished activation of the E183-specific T cell clone used 10 . We then introduced the V152E mutation into the co-agonist sc GAG-HLA-A2, and co-expressed WT or V152E sc GAG-HLA-A2 with low levels of agonist sc E183-HLA-A2. Both WT and V152E sc GAG-HLA-A2 enhanced IFN-γ production and degranulation (Figure 3C,D) , suggesting that TCR binding to co-agonist pMHC is not required for co-agonist pMHC-dependent CD8+ T cell activation enhancement. Single chain MHC class I technology, as presented here, can be used to modify TCR and/or coreceptor binding to MHC class I with known peptide to investigate the molecular requirements for T cell antigen recognition and activation.
Discussion
The presented protocol provides a robust tool for investigation of molecular interactions during human CD8+ T cell activation. A critical step for investigation of co-agonism during human T cell activation is control over agonist pMHC cell surface expression to ensure equal agonist pMHC presentation on the APCs with or without co-agonist pMHC expression. In our experimental system, this is achieved by using a single cell clone expressing low amounts of agonist pMHC, followed by supertransfection with a co-agonist pMHC construct and agonist pMHC quantification using TCR-like antibody 10, 32 . As agonist sc pMHC expression can change over time, it is critical to quantify agonist pMHC surface expression on APCs used in each experiment using TCR-like antibodies. If no specific TCR-like antibody is available, agonist scMHC-I can be expressed as fluorescent protein fusion, and its cell surface expression can then be quantified using a sensitive microscopy method, such as total internal reflection fluorescence microscopy 35, 36 . Moreover, cell surface expression of co-agonist pMHC decreases over time, due to methylationdependent and -independent silencing of the CMV promoter 37 , and should be monitored using antibody staining and flow cytometry analysis, with repeated FACS-sorting when needed. We have cultured CHO cells for up to 5 weeks with relatively limited loss of sc pMHC expression. We highly recommend freezing the CHO cells soon after selection/sorting to ensure a reliable stock of cells with known sc MHC expression.
The several steps of the presented protocols can be modified, depending on the availability of equipment, or depending on the specific research aims. For example, PBMC proliferation potential can be inhibited (Step 3.2.1) using alternative methods that do not require a gamma (or X-) irradiator, such as treatment with mitomycin C 38 . A non-enzymatic cell dissociation buffers containing metal chelators 39 can be used instead of cell scraping in step 3.3.1. Moreover, the antigen presenting system can be modified to make it more suitable for human CTL clones expressing different TCRs. CHO cells express hamster MHC class I molecules, and although these are irrelevant for the CTL line studied here (Figure 2A and Figure 3A , we observed no T cell responses to untransfected CHO cells), there is a possibility that other human TCRs may show some xenoreactivity. In that case, hamster MHC class I expression can be reduced by knocking out hamster β2-microglubulin or TAP using CRISPR/ Cas9; or a human APC line can be used after CRISPR/Cas9-mediated β2-microglubulin or TAP knock out.
The experimental system presented here allows precise control of TCR and CD8 interactions with MHC molecules presenting pre-defined peptides. For example, we have previously shown that mutations abolishing CD8 binding 40 to coagonist pMHC eliminated coagonist-mediated activation enhancement in murine and human CD8+ T cells 9, 10 , whereas abrogating TCR interaction with co-agonist pMHC had no effect on coagonist-mediated activation enhancement 10 . However, the use of single chain MHC constructs has several limitations. For example, it is time and labor-consuming to test multiple co-agonist peptide sequences using this experimental system, as this involves generation of multiple plasmids encoding sc MHC with different peptides, and subsequent transfections and cell sorting. Previously, we used the murine TAP-deficient cell line RMA-S to test multiple co-agonist peptides in mouse T cell activation 8, 9 , but this approach was not successful with the TAP-deficient human T2 cell line 10 , most likely due to presentation of TAP-independent peptides 41 . Another limitation of our experimental system is that is does not provide a fast method for altering the amount of co-agonist pMHC molecules for the purpose of determining the critical amount of coagonist pMHC required to trigger T cell activation. Moreover, the tetracycline-inducible system used does not allow titration of agonist pMHC quantity at the single cell level by changing the tetracycline concentration, as varying tetracycline concentration alters the proportion of HLA-A2 positive cells, rather than HLA-A2 levels on per cell basis. An alternative approach that we are currently investigating is to use supported lipid bilayers 42 , previously used to investigate co-agonism during murine CD4+ T cell activation 4 or beads presenting fixed amount of agonist pMHC in the presence of varying amounts of co-agonist pMHC. When used in conjunction with UV-cleavable peptide technology 4, 43 , these alternative experimental systems should allow fast testing of multiple co-agonist peptide sequences as well as different amounts of co-agonist pMHC.
The sc MHC technology can be also applicable to investigation of co-agonism in human or murine CD4 T cells, as single chain MHC class II molecules presenting pre-determined peptides have been successfully expressed on mammalian cell surfaces 44 . Moreover, the use of sc MHC technology can be extended to investigation of non-classical MHC molecules such as HLA-E. Sc HLA-E has been described before, and its expression has been shown to inhibit human T cell activation 45 . Another non-classical MHC molecule of interest is CD1, which presents lipids instead of peptides 46 . Sc constructs consisting of CD1 heavy chain and β2-microglobulin have been shown to be expressed on the cell surface and to bind relevant lipid ligands 47 . Single chain MHC technology has great potential as a research tool for investigating molecular interactions during T and NK cell activation.
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